Currently Recruiting CTN Supported Trials

SPRINT-SARI

SPRINT-SARI

SPRINT-SARI (Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection) is an international, multi-centre, prospective, short period incidence observational study of patients in participating hospitals and intensive care units (ICUs) with severe acute respiratory infection (SARI).

The primary aim of this study is to establish a research response capability for a future epidemic / pandemic through a global SARI observational study. The secondary aim of this study is to investigate the descriptive epidemiology and microbiology profiles of patients with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory and Logistic (EARL) barriers to conducting pandemic research on a global level.

SARI continues to be of major relevance to public health worldwide. In the last 10 years there have been multiple SARI outbreaks around the world.  The 2009 H1N1 pandemic was estimated to result in more than 200,000 respiratory deaths globally. The World Health Organization (WHO) defines SARI as an acute respiratory infection of recent onset (within 10 days) requiring hospitalisation, manifested by fever (≥38°C) or a history of fever and cough. There is international consensus that it is important to undertake observational studies of patients with SARI as an essential component of pandemic and epidemic research preparedness.

SPRINT-SARI Ireland was set up to during the COVD-19 pandemic to capture irish patients Contact: For further information about this study, please email This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more


REMAP-CAP

REMAP-CAP

Severe community-acquired pneumonia (severe CAP) is a major cause of mortality. The REMAP-CAP Trial is a multi-centre randomised controlled platform trial utilising Bayesian adaptive methods for 4000 European and 2800 Australian and New Zealand ICU patients with severe CAP.

Read more


TEAM ICU

TEAM ICU

A prospective multi-centre phase III randomised controlled Trial of Early Activity and Mobilisation compared with standard care in invasively ventilated patients in intensive care

Read more


TTM2

TTM2

The TTM2 trial is an international, multicentre, parallel group, non-commercial, randomised, superiority trial in which a target temperature of 33°C after cardiac arrest will be compared with normothermia and early treatment of fever (Ø37.8°C) Patients eligible for inclusion will be unconscious adult patients with out-of-hospital cardiac arrest of a presumed cardiac cause with stable return of spontaneous circulation. Randomisation will be performed by a healthcare professional in the emergency department, in the angiography suite or in the intensive care unit via web-based application using permuted blocks with varying sizes, stratified by site. Due to the nature of the intervention, health care staff will not be blinded to the intervention. However, outcome assessors, prognosticators, statisticians and conclusion drawers will be blinded to group allocation.

Read more